Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | $ 970.00 |
Description | Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD). |
In vitro | Zevaquenabant can simultaneously inhibit CB1 receptors and iNOS in peripheral organs[1]. |
In vivo | Zevaquenabant (3 mg/kg; p.o.; for 28 days) significantly enhances renal morphology and function in diet-induced obese mice[1]. Employing 6-week-old male C57Bl/6J mice as an animal model for diet-induced obesity[1], administration of Zevaquenabant resulted in marked improvements in kidney health and performance. |
Synonyms | (S)-MRI-1867 |
Molecular Weight | 547.98 |
Formula | C25H21ClF3N5O2S |
CAS No. | 1998760-00-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Zevaquenabant 1998760-00-1 MRI 1867 MRI1867 (S)-MRI-1867 MRI-1867 inhibitor inhibit